ID

36897

Description

A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02424513

Lien

https://clinicaltrials.gov/show/NCT02424513

Mots-clés

Versions (1)
  1. 19/06/2019 19/06/2019 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

19 juin 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Prostate Cancer NCT02424513

Anglais

Eligibility Prostate Cancer NCT02424513

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. histological diagnosis of prostate adenocarcinoma.
Description

Adenocarcinoma of prostate

Type de données

boolean

Alias
UMLS CUI [1]
C0007112
2. patients considered candidates for radical prostatectomy and pelvic lymph node dissection. these patients may or may not have identified nodal metastasis on conventional imaging but would still be candidates for radical prostatectomy and pelvic lymph node dissection.
Description

Patients Appropriate Radical prostatectomy | Patients Appropriate Pelvic lymphadenectomy | Secondary malignant neoplasm of lymph node Imaging | Secondary malignant neoplasm of lymph node Absent Imaging

Type de données

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C1548787
UMLS CUI [1,3]
C0194810
UMLS CUI [2,1]
C0030705
UMLS CUI [2,2]
C1548787
UMLS CUI [2,3]
C0193883
UMLS CUI [3,1]
C0686619
UMLS CUI [3,2]
C0011923
UMLS CUI [4,1]
C0686619
UMLS CUI [4,2]
C0332197
UMLS CUI [4,3]
C0011923
3. patients, who are at high-risk for pelvic lymph node metastasis as defined by a lymph node involvement risk of greater than or equal to 20% using the briganti nomogram.
Description

High risk of Secondary malignant neoplasm of lymph node Pelvic | Risk Percentage Lymph Node Involvement Nomogram

Type de données

boolean

Alias
UMLS CUI [1,1]
C0332167
UMLS CUI [1,2]
C0686619
UMLS CUI [1,3]
C0030797
UMLS CUI [2,1]
C0035647
UMLS CUI [2,2]
C0439165
UMLS CUI [2,3]
C0806692
UMLS CUI [2,4]
C1450294
4. age ≥ 18 years.
Description

Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
5. ability to understand and willingness to sign irb approved consent form
Description

Informed Consent

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
6. for men of child-producing potential, the use of effective contraceptive methods during the study.
Description

Male fertility Contraceptive methods

Type de données

boolean

Alias
UMLS CUI [1,1]
C1955321
UMLS CUI [1,2]
C0700589
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. treatment or plans for treatment with radiation therapy, surgery, chemotherapy, or investigational therapy between the time of conventional imaging, [89]zr-df-iab2m pet/ct and the surgical resection or biopsy procedures used for the study evaluation.
Description

Therapeutic radiology procedure | Operative Surgical Procedures | Chemotherapy | Therapies, Investigational

Type de données

boolean

Alias
UMLS CUI [1]
C1522449
UMLS CUI [2]
C0543467
UMLS CUI [3]
C0392920
UMLS CUI [4]
C0949266
2. unwillingness or inability to comply with procedures required in this protocol.
Description

Protocol Compliance Unwilling | Protocol Compliance Unable

Type de données

boolean

Alias
UMLS CUI [1,1]
C0525058
UMLS CUI [1,2]
C0558080
UMLS CUI [2,1]
C0525058
UMLS CUI [2,2]
C1299582
3. other cancers that might potentially interfere with the reading and interpretation of [89]zr-df-iab2m pet/ct scans.
Description

Cancer Other | Interference Interpretation Zirconium Zr 89 Df-IAB2M PET/CT scan

Type de données

boolean

Alias
UMLS CUI [1]
C1707251
UMLS CUI [2,1]
C0521102
UMLS CUI [2,2]
C0459471
UMLS CUI [2,3]
C3827037
UMLS CUI [2,4]
C1699633
4. patients who are currently receiving any other investigational agent.
Description

Investigational New Drugs

Type de données

boolean

Alias
UMLS CUI [1]
C0013230
5. patients who have had or are currently receiving androgen deprivation therapy
Description

Antiandrogen therapy

Type de données

boolean

Alias
UMLS CUI [1]
C0279492
Retour au début de la page

Similar models

Eligibility Prostate Cancer NCT02424513

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Adenocarcinoma of prostate
Item
1. histological diagnosis of prostate adenocarcinoma.
boolean
C0007112 (UMLS CUI [1])
Patients Appropriate Radical prostatectomy | Patients Appropriate Pelvic lymphadenectomy | Secondary malignant neoplasm of lymph node Imaging | Secondary malignant neoplasm of lymph node Absent Imaging
Item
2. patients considered candidates for radical prostatectomy and pelvic lymph node dissection. these patients may or may not have identified nodal metastasis on conventional imaging but would still be candidates for radical prostatectomy and pelvic lymph node dissection.
boolean
C0030705 (UMLS CUI [1,1])
C1548787 (UMLS CUI [1,2])
C0194810 (UMLS CUI [1,3])
C0030705 (UMLS CUI [2,1])
C1548787 (UMLS CUI [2,2])
C0193883 (UMLS CUI [2,3])
C0686619 (UMLS CUI [3,1])
C0011923 (UMLS CUI [3,2])
C0686619 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
C0011923 (UMLS CUI [4,3])
High risk of Secondary malignant neoplasm of lymph node Pelvic | Risk Percentage Lymph Node Involvement Nomogram
Item
3. patients, who are at high-risk for pelvic lymph node metastasis as defined by a lymph node involvement risk of greater than or equal to 20% using the briganti nomogram.
boolean
C0332167 (UMLS CUI [1,1])
C0686619 (UMLS CUI [1,2])
C0030797 (UMLS CUI [1,3])
C0035647 (UMLS CUI [2,1])
C0439165 (UMLS CUI [2,2])
C0806692 (UMLS CUI [2,3])
C1450294 (UMLS CUI [2,4])
Age
Item
4. age ≥ 18 years.
boolean
C0001779 (UMLS CUI [1])
Informed Consent
Item
5. ability to understand and willingness to sign irb approved consent form
boolean
C0021430 (UMLS CUI [1])
Male fertility Contraceptive methods
Item
6. for men of child-producing potential, the use of effective contraceptive methods during the study.
boolean
C1955321 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Therapeutic radiology procedure | Operative Surgical Procedures | Chemotherapy | Therapies, Investigational
Item
1. treatment or plans for treatment with radiation therapy, surgery, chemotherapy, or investigational therapy between the time of conventional imaging, [89]zr-df-iab2m pet/ct and the surgical resection or biopsy procedures used for the study evaluation.
boolean
C1522449 (UMLS CUI [1])
C0543467 (UMLS CUI [2])
C0392920 (UMLS CUI [3])
C0949266 (UMLS CUI [4])
Protocol Compliance Unwilling | Protocol Compliance Unable
Item
2. unwillingness or inability to comply with procedures required in this protocol.
boolean
C0525058 (UMLS CUI [1,1])
C0558080 (UMLS CUI [1,2])
C0525058 (UMLS CUI [2,1])
C1299582 (UMLS CUI [2,2])
Cancer Other | Interference Interpretation Zirconium Zr 89 Df-IAB2M PET/CT scan
Item
3. other cancers that might potentially interfere with the reading and interpretation of [89]zr-df-iab2m pet/ct scans.
boolean
C1707251 (UMLS CUI [1])
C0521102 (UMLS CUI [2,1])
C0459471 (UMLS CUI [2,2])
C3827037 (UMLS CUI [2,3])
C1699633 (UMLS CUI [2,4])
Investigational New Drugs
Item
4. patients who are currently receiving any other investigational agent.
boolean
C0013230 (UMLS CUI [1])
Antiandrogen therapy
Item
5. patients who have had or are currently receiving androgen deprivation therapy
boolean
C0279492 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial